REGENERON PHARMACEUTICALS, INC. — Director's Dealing 2012

Feb 2, 2012

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: REGENERON PHARMACEUTICALS INC (REGN)
CIK: 0000872589
Period of Report: 2012-01-31

Reporting Person: GOLDBERG MURRAY A (SVP Finance and Admin CFO Trea)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2012-01-26	Common Stock	G	2250	—	Disposed	87111	Direct
2012-01-31	Common Stock	M	28079	$20.32	Acquired	115190	Direct
2012-01-31	Common Stock	F	6334	$90.07	Disposed	108856	Direct
2012-01-31	Common Stock	F	10017	$90.07	Disposed	98839	Direct
2012-01-31	Common Stock	M	16000	$21.92	Acquired	114839	Direct
2012-01-31	Common Stock	F	3893	$90.07	Disposed	110946	Direct
2012-01-31	Common Stock	F	5577	$90.07	Disposed	105369	Direct
2012-02-01	Common Stock	S	3015	$90.64	Disposed	102354	Direct
2012-02-01	Common Stock	S	7151	$91.71	Disposed	95203	Direct
2012-02-01	Common Stock	S	7992	$92.22	Disposed	87211	Direct
2012-02-01	Common Stock	S	100	$93.04	Disposed	87111	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2012-01-31	Non-Qualified Stock Option (right to buy)	$20.32	M	28079	Disposed	2016-12-18	Common Stock (28079)	Direct
2012-01-31	Non-Qualified Stock Option (right to buy)	$21.92	M	16000	Disposed	2017-12-17	Common Stock (16000)	Direct
2012-01-31	Non-Qualified Stock Option (right to buy)	$90.07	A	6334	Acquired	2016-12-18	Common Stock (6334)	Direct
2012-01-31	Non-Qualified Stock Option (right to buy)	$90.07	A	3893	Acquired	2017-12-17	Common Stock (3893)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	5416	Indirect

Footnotes

F1: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).

F2: Represents volume-weighted average price of sales of 3,015 shares of Company stock on February 1, 2012 at prices ranging from $90.06 to $90.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 1, 2012 at each separate price.

F3: Represents volume-weighted average price of sales of 7,151 shares of Company stock on February 1, 2012 at prices ranging from $91.00 to $91.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 1, 2012 at each separate price.

F4: Represents volume-weighted average price of sales of 7,992 shares of Company stock on February 1, 2012 at prices ranging from $92.00 to $92.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 1, 2012 at each separate price.

F5: The stock option award (combined incentive stock option and non-qualified stock option) vests in four equal annual installments, commencing one year after the date of grant.

F6: Exercisable date, exercise date, exercise price, purchase price, sales price, and/or expiration date is/are not applicable in this case.